Table 1—

Baseline characteristics per intervention group

Placebo500 μg1,000 μg
n171415
Sex (male)10 (59)4 (29)5 (33)
Age (years)62 ± 7.560 ± 8.859 ± 6.4
Diabetes duration (years)18.4 ± 8.312.5 ± 5.010.9 ± 6.3
Total dose of insulin (units)90 ± 26105 ± 4378 ± 22
A1C (%)9.41 ± 1.019.43 ± 1.029.67 ± 0.91
Systolic blood pressure (mmHg)159 ± 20147 ± 24156 ± 25
Diastolic blood pressure (mmHg)83 ± 1085 ± 1084 ± 14
BMI (kg/m2)34 ± 4.335 ± 7.233 ± 4.2
Total cholesterol (mmol/l)5.00 ± 0.994.85 ± 0.754.47 ± 0.85
Total-to-HDL cholesterol ratio4.50 ± 1.13.72 ± 1.403.85 ± 1.29
Triglycerides (mmol/l)2.1 ± 1.22.0 ± 1.31.9 ± 1.1
HDL (mmol/l)1.15 ± 0.261.47 ± 0.541.26 ± 0.40
LDL (mmol/l)2.90 ± 1.022.50 ± 0.482.34 ± 0.75
Chromium (nmol/l)*1015 (10–37)14 (10–32)
  • Data are means ± SD, mean (range), or n (%).

  • * No patient in the placebo group had at baseline a chromium concentration >10 nmol/l.